Document is current
Any future updates will be listed below
-
Authors
Lammers, Eline M. J.
Nijdam, Annelies
Zijlstra, Josée M.
Janus, Cécile P. M.
de Weijer, Roel J.
Appelman, Yolande
Manintveld, Olivier C.
Teske, Arco J.
van Leeuwen, Flora E.
Aleman, Berthe M. P.
-
Funding
Funding for this research was provided by:
ZonMw (10330022010009, 10330022010009)
KWF Kankerbestrijding (NKI 2011-5270)
- License Information
-
More Information
Article History
Received: 20 August 2023
Accepted: 2 March 2024
First Online: 23 April 2024
Declarations
:
: This observational study was exempt from institutional review board approval according to Dutch law.
: Survivors who objected to the use of their medical data for research purposes were not included in the study.
: Yolande Appelman has received a research grant from the Dutch Heart Foundation and from Abbott Cardiovascular. Olivier C. Manintveld has participated in advisory boards of, and/or has received speaker allowances from Abbott, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Novartis and Vifor Pharma. The other authors have no conflicts of interest to declare.
